RemeGen Co., Ltd., a commercial-stage biotechnology company, announced on December 7, 2022, that its latest antibody-drug conjugate, RC118 for injection, has been granted two orphan drug designations by the United States Food and Drug Administration for gastric cancer and pancreatic cancer.
December 12, 2022
· 5 min read